<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40784">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02575443</url>
  </required_header>
  <id_info>
    <org_study_id>ADMS NMD depth</org_study_id>
    <nct_id>NCT02575443</nct_id>
  </id_info>
  <brief_title>Neuromuscular Block and Anesthetic Depth Monitoring</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluated whether the depth of neuromuscular block may
      affect the unicon value of anesthetic depth monitoring system (ADMS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of Unicon value presented on the anesthetic depth monitoring system</measure>
    <time_frame>through study completion, an average of 2 hours</time_frame>
    <description>Every 15 min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total infused dose of propofol</measure>
    <time_frame>At 1 min after the anesthesia is finished</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total infused dose of rocuronium</measure>
    <time_frame>At 1 minute after the anesthesia is finished</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cholecystectomy, Laparoscopic</condition>
  <arm_group>
    <arm_group_label>Moderate block (MB) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Deep block (DB) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium (MB group)</intervention_name>
    <description>Count of train-of-four: 1-2 Titration of rocuronium dose</description>
    <arm_group_label>Moderate block (MB) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium (DB group)</intervention_name>
    <description>Post-tetanic count: 1-2 Titration of rocuronium dose</description>
    <arm_group_label>Deep block (DB) group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gall bladder disease

          -  American Society of Anesthesiologist physical status 1 or 2

        Exclusion Criteria:

          -  Pregnancy

          -  Body mass index &lt; 16

          -  Body mass index &gt;30

          -  Neuromuscular disease

          -  Previous intraabdominal surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Seok Na</last_name>
    <role>Principal Investigator</role>
    <affiliation>82, Gumi 173</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyo-Seok Na</last_name>
    <phone>+821087012913</phone>
    <email>hsknana@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo-Seok Na</last_name>
      <phone>+821087012913</phone>
      <email>hsknana@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 27, 2016</lastchanged_date>
  <firstreceived_date>October 6, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Hyo-Seok Na</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
